Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.
At Carolina Blood and Cancer Care Associates, where Sashi Naidu, MD, is director of research, the No One Left Alone (NOLA) initiative, first implemented in January 2021, is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing their equitable access to care.
Transcript
What is the status of phase 2A of NOLA, whose focus is to expand genetic testing/next-generation sequencing and/or optimize biomarker testing?
The next phase, which we’ve just undertaken, is to partner with molecular diagnostic labs to increase the utilization and uptake of next-gen sequencing and biomarker testing in our rural patient population. The purpose of this is to not only optimize cancer care and bring potential for the latest therapeutics to our patient population who normally would not have access to this type of care, but to also foster a level of comfort between the patients and the labs, to say that they’re partnering with us and through us to improve their care generally. So, it’s been a very positive process so far.
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More